116 results

Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

Saraceni, Francesco; Labopin, Myriam; Raiola, Anna M.; More

HemaSphere. 7(10):e952, October 2023.

Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France

Darlington, Meryl; Sujobert, Pierre; Kosmider, Olivier; More

HemaSphere. 7(9):e943, September 2023.

Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA

Efficace, Fabio; Al Essa, Wael; Platzbecker, Uwe; More

HemaSphere. 7(9):e944, September 2023.

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia

Alvarez-Larrán, Alberto; Cuevas, Beatriz; Velez, Patricia; More

HemaSphere. 7(8):e936, August 2023.

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT

Kharfan-Dabaja, Mohamed A.; Labopin, Myriam; Ayala, Ernesto; More

HemaSphere. 7(7):e920, July 2023.

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial

Gaidzik, Verena I.; Paschka, Peter; Schlenk, Richard F.; More

HemaSphere. 7(5):e877, May 2023.

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Wille, Kai; Brouka, Maja; Bernhardt, Johannes; More

HemaSphere. 7(5):e882, May 2023.

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT

Robin, Marie; de Wreede, Liesbeth C.; Schroeder, Thomas; More

HemaSphere. 7(4):e851, April 2023.

Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

Pagano, Livio; Zinzani, Pier Luigi; Pileri, Stefano; More

HemaSphere. 7(3):e841, March 2023.

Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders

Dussiau, Charles; Dupuy, Henry; Bidet, Audrey; More

HemaSphere. 7(3):e847, March 2023.

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients

Malighetti, Federica; Arosio, Giulia; Manfroni, Chiara; More

HemaSphere. 7(3):e852, March 2023.

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

Dal Bello, Reinaldo; Pacchiardi, Kim; Chauvel, Clémentine; More

HemaSphere. 7(1):e819, January 2023.

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Mosquera-Orgueira, Adrián; Pérez-Encinas, Manuel; Hernández-Sánchez, Alberto; More

HemaSphere. 7(1):e818, January 2023.

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Kirschner, Martin; Rolles, Benjamin; Crysandt, Martina; More

HemaSphere. 6(11):e787, November 2022.

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients

Le Pannérer, Marguerite-Marie; Diesch, Jeannine; Casquero, Raquel; More

HemaSphere. 6(11):e792, November 2022.

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis

Gagelmann, Nico; Salit, Rachel B.; Schroeder, Thomas; More

HemaSphere. 6(10):e784, October 2022.

Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: “Real World” Data From Germany

Braitsch, Krischan; Schmalbrock, Laura K.; Jung, Paul; More

HemaSphere. 6(9):e759, September 2022.

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Harrison, Claire; Heidel, Florian H.; Vannucchi, Alessandro M.; More

HemaSphere. 6(8):e757, August 2022.

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Rüfer, Axel; Angermann, Hubert; Benz, Rudolf; More

HemaSphere. 6(7):e741, July 2022.

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

Tremblay, Douglas; Srisuwananukorn, Andrew; Ronner, Lukas; More

HemaSphere. 6(6):e721, June 2022.

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

Nielsen, Amalie Bach; Hansen, Jakob Werner; Ørskov, Andreas Due; More

HemaSphere. 6(5):e0713, May 2022.

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

Wester, Ruth; Dinmohamed, Avinash G.; van der Holt, Bronno; More

HemaSphere. 6(2):e683, February 2022.

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Tettero, Jesse M.; Freeman, Sylvie; Buecklein, Veit; More

HemaSphere. 6(1):e676, January 2022.

Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience

Alary, Anne Sophie; Maute, Carole; Kosmider, Olivier; More

HemaSphere. 5(12):e658, December 2021.

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

Estrada, Natalia; Xicoy, Blanca; Beier, Fabian; More

HemaSphere. 5(12):e657, December 2021.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

Valent, Peter; Akin, Cem; Hartmann, Karin; More

HemaSphere. 5(11):e646, November 2021.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

Beitzen-Heineke, Antonia; Berenbrok, Nikolaus; Waizenegger, Jonas; More

HemaSphere. 5(9):e630, September 2021.

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Khalife-Hachem, Sabine; Saleh, Khalil; Pasquier, Florence; More

HemaSphere. 5(9):e632, September 2021.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Döhner, Hartmut; Symeonidis, Argiris; Deeren, Dries; More

HemaSphere. 5(8):e617, August 2021.

Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

Secardin, Lise; Gomez Limia, Cintia; da Silva-Benedito, Suzana; More

HemaSphere. 5(7):e593, July 2021.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

Saunders, Jamie; Curto-Garcia, Natalia; Sriskandarajah, Priya; More

HemaSphere. 5(7):e609, July 2021.

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

Khan, Alesia; Woodley, Claire; Radia, Deepti; More

HemaSphere. 5(7):e611, July 2021.

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e562, May 2021.

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Mesa, Ruben A.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e553, May 2021.

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Feld, Jonathan; Tremblay, Douglas; Dougherty, Mikaela; More

HemaSphere. 5(4):e549, April 2021.

Next-generation Sequencing in Bone Marrow Failure Syndromes and Isolated Cytopenias: Experience of the Spanish Network on Bone Marrow Failure Syndromes

Gálvez, Eva; Vallespín, Elena; Arias-Salgado, Elena G.; More

HemaSphere. 5(4):e539, April 2021.

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection

Banck, Jan Christoph; Mueller, Niklas; Mellinghoff, Sibylle Christiane; More

HemaSphere. 5(3):e530, March 2021.

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies

Hayette, Sandrine; Grange, Béatrice; Vallee, Maxime; More

HemaSphere. 5(2):e522, February 2021.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Gisslinger, Heinz; Klade, Christoph; Georgiev, Pencho; More

HemaSphere. 4(6):e485, December 2020.

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

Fontana, Diletta; Ramazzotti, Daniele; Aroldi, Andrea; More

HemaSphere. 4(6):e497, December 2020.

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7

Kunimoto, Hiroyoshi; Fukuchi, Yumi; Murakami, Koichi; More

HemaSphere. 4(5):e469, October 2020.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Mossuto, Sandra; Attardi, Enrico; Alesiani, Francesco; More

HemaSphere. 4(5):e483, October 2020.